scinapse is loading now...
  • References (26)
  • Citations (0)
Published on Apr 23, 2018in The Journal of Infectious Diseases 5.19
Dorothy A. Machalek12
Estimated H-index: 12
(University of Melbourne),
Suzanne M. Garland61
Estimated H-index: 61
(University of Melbourne)
+ 8 AuthorsJohn M. Kaldor86
Estimated H-index: 86
(University of New South Wales)
23 Citations Source Cite
Published on Feb 1, 2018in Human Vaccines & Immunotherapeutics 2.23
Lina S. Sy16
Estimated H-index: 16
(Kaiser Permanente),
Kristin Meyer1
Estimated H-index: 1
(Kaiser Permanente)
+ 10 AuthorsJohn Hansen21
Estimated H-index: 21
(Kaiser Permanente)
ABSTRACTLimited safety data are available on inadvertent exposure to quadrivalent human papillomavirus vaccine (4vHPV) during pregnancy. We conducted a descriptive observational postlicensure safety surveillance study in Kaiser Permanente Southern California and Northern California to assess congenital anomaly and miscarriage among pregnancies exposed to 4vHPV. Using electronic medical records, we identified women who received a dose of 4vHPV between August 2006 and March 2008 within 30 days pre...
3 Citations Source Cite
Published on Jan 18, 2018in Clinical Infectious Diseases 9.12
Susanne K. Kjaer71
Estimated H-index: 71
(University of Copenhagen),
Mari Nygård19
Estimated H-index: 19
+ 11 AuthorsMaria Hortlund9
Estimated H-index: 9
(Karolinska Institutet)
16 Citations Source Cite
Published on Jan 4, 2018in The Journal of Infectious Diseases 5.19
Daniel Novakovic4
Estimated H-index: 4
(University of Sydney),
Alan T. L. Cheng3
Estimated H-index: 3
(University of Sydney)
+ 13 AuthorsShyan Vijayasekaran14
Estimated H-index: 14
(Princess Margaret Hospital for Children)
11 Citations Source Cite
Published on Dec 1, 2017in Pediatrics 5.51
Daron Gale Ferris45
Estimated H-index: 45
Rudiwilai Samakoses8
Estimated H-index: 8
+ 10 AuthorsJian Li Chu1
Estimated H-index: 1
(Merck & Co.)
OBJECTIVES: We describe the final 10-year data for the long-term follow-up study of the 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents. METHODS: In the base study (V501-018), 1661 sexually inactive boys and girls received the 4vHPV vaccine (early vaccination group [EVG], managed for 9.9 years) or a placebo at day 1, month 2, and month 6. Thereafter, at month 30, the placebo group (catch-up vaccination group [CVG], managed for 7.4 years) received the 4vHPV vaccine...
6 Citations Source Cite
Published on Nov 1, 2017in The Lancet 53.25
Warner K. Huh43
Estimated H-index: 43
(University of Alabama at Birmingham),
Elmar A. Joura32
Estimated H-index: 32
(Medical University of Vienna)
+ 25 AuthorsAngelica Lindén Hirschberg34
Estimated H-index: 34
(Karolinska University Hospital)
Summary Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and a...
38 Citations Source Cite
Published on Sep 1, 2017in Obstetrics & Gynecology 4.98
Heather S. Lipkind19
Estimated H-index: 19
Gabriela Vazquez-Benitez12
Estimated H-index: 12
+ 9 AuthorsGrace M. Lee49
Estimated H-index: 49
OBJECTIVE:To evaluate whether quadrivalent human papillomavirus vaccine (4vHPV) administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects.METHODS:We conducte
6 Citations Source Cite
Published on May 1, 2017in Respiratory Medicine 3.23
Helena Ribeiro Fortes2
Estimated H-index: 2
(Federal University of Rio de Janeiro),
Felipe Mussi von Ranke5
Estimated H-index: 5
(Federal Fluminense University)
+ 5 AuthorsEdson Marchiori32
Estimated H-index: 32
(Federal University of Rio de Janeiro)
Abstract Recurrent respiratory papillomatosis (RRP) is a benign disease of the upper aero-digestive tract caused by human papillomavirus (HPV) infection, which affects children and young adults. The aim of this review is to describe the main etiological, epidemiological, clinical, diagnostic, and treatment aspects of RRP. Most infections in children occur at birth, during passage through the birth canals of contaminated mothers. In adults, HPV is transmitted sexually. Papillomas usually appear a...
13 Citations Source Cite
Published on Mar 30, 2017in The New England Journal of Medicine 79.26
Nikolai Madrid Scheller4
Estimated H-index: 4
Björn Pasternak27
Estimated H-index: 27
+ 2 AuthorsAnders Hviid34
Estimated H-index: 34
BackgroundThe quadrivalent human papillomavirus (HPV) vaccine is recommended for all girls and women 9 to 26 years of age. Some women will have inadvertent exposure to vaccination during early pregnancy, but few data exist regarding the safety of the quadrivalent HPV vaccine in this context. MethodsWe assessed a cohort that included all the women in Denmark who had a pregnancy ending between October 1, 2006, and November 30, 2013. Using nationwide registers, we linked information on vaccination,...
25 Citations Source Cite
Published on Aug 1, 2016in Pediatrics 5.51
Edson D. Moreira9
Estimated H-index: 9
(Obras Sociais Irmã Dulce),
Stan L. Block14
Estimated H-index: 14
+ 20 AuthorsJacob Bornstein29
Estimated H-index: 29
(Bar-Ilan University)
OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at entry), 9 to 26 years of age. METHODS: Vaccination was administered as a 3-dose regimen at day 1, and months 2 and 6. More than 15 000 subjects received ≥1 dose of 9vHPV vaccine. In 2 of the studies, >7000 control subjects received ≥1 dose of quadrivalent HPV (qHPV) vaccine. Serious and nonserious adverse events (AEs)...
31 Citations Source Cite
Cited By0